Zoetis (ZTS) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
8 Apr, 2026Purpose and vision
Aims to nurture the world by advancing animal care and aspires to be the most trusted and valued animal health company through innovation and customer focus.
Business overview and scale
Operates in over 100 countries with $9.5B annual revenue and 14,500 employees.
Offers medicines, vaccines, diagnostics, biodevices, and genetic tests across 8 core species and 7 product categories.
70% of revenue comes from companion animal products, 30% from livestock.
18 blockbuster products each generate over $100M annually.
Leadership and strategic priorities
Executive team led by CEO Kristin Peck, with leaders across manufacturing, R&D, finance, and digital.
Strategic priorities include innovation, customer experience, digital solutions, workplace culture, sustainability, and operational excellence.
Latest events from Zoetis
- 2026 proxy details strong growth, governance, and sustainability, with key votes on directors and pay.ZTS
Proxy filing8 Apr 2026 - Key votes include director elections, say-on-pay, auditor ratification, and written consent rights.ZTS
Proxy filing8 Apr 2026 - Growth in 2026 will be led by parasiticides, innovation in long-acting therapies, and expanding franchises.ZTS
2026 KeyBanc Capital Markets Healthcare Forum17 Mar 2026 - Triple combination parasiticides and livestock drive growth amid resilient global demand.ZTS
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - Strong product innovation and market expansion drive growth amid resilient pet health spending.ZTS
Leerink Global Healthcare Conference 20269 Mar 2026 - 2026 guidance reflects resilience, innovation, and a synchronized global reporting calendar.ZTS
BofA Securities Animal Health Summit26 Feb 2026 - 2025 saw 6% organic growth, robust franchises, and strong 2026 guidance for further gains.ZTS
Q4 202512 Feb 2026 - Strong Q1 growth, robust innovation pipeline, and expanding alternative channels drive outlook.ZTS
Stifel Jaws & Paws Conference 20253 Feb 2026 - Q2 revenue up 11% operationally, adjusted net income up 18%, and $6B buyback approved.ZTS
Q2 20242 Feb 2026